MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
MELBOURNE, Australia AND SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
A rare and fatal brain disorder with no available treatment or cure. One that attacks the nervous system, balance, and the ability to move. This is the reality for patients with multiple system ...
(MENAFN- GlobeNewsWire - Nasdaq) – Alterity's novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA – – End-of-Phase 2 FDA Meeting on track for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results